JP2021536462A5 - - Google Patents

Info

Publication number
JP2021536462A5
JP2021536462A5 JP2021512448A JP2021512448A JP2021536462A5 JP 2021536462 A5 JP2021536462 A5 JP 2021536462A5 JP 2021512448 A JP2021512448 A JP 2021512448A JP 2021512448 A JP2021512448 A JP 2021512448A JP 2021536462 A5 JP2021536462 A5 JP 2021536462A5
Authority
JP
Japan
Prior art keywords
group
alkyl
heterocyclyl
cycloalkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021512448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021536462A (ja
JP7477177B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/049971 external-priority patent/WO2020051465A1/en
Publication of JP2021536462A publication Critical patent/JP2021536462A/ja
Publication of JP2021536462A5 publication Critical patent/JP2021536462A5/ja
Application granted granted Critical
Publication of JP7477177B2 publication Critical patent/JP7477177B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021512448A 2018-09-07 2019-09-06 毒性が低減されたハイブリッドアムホテリシンb誘導体 Active JP7477177B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862728203P 2018-09-07 2018-09-07
US62/728,203 2018-09-07
PCT/US2019/049971 WO2020051465A1 (en) 2018-09-07 2019-09-06 Hybrid amphotericin b derivatives with reduced toxicity

Publications (3)

Publication Number Publication Date
JP2021536462A JP2021536462A (ja) 2021-12-27
JP2021536462A5 true JP2021536462A5 (enExample) 2022-09-09
JP7477177B2 JP7477177B2 (ja) 2024-05-01

Family

ID=69719049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021512448A Active JP7477177B2 (ja) 2018-09-07 2019-09-06 毒性が低減されたハイブリッドアムホテリシンb誘導体

Country Status (8)

Country Link
US (1) US11198705B2 (enExample)
EP (1) EP3846823A4 (enExample)
JP (1) JP7477177B2 (enExample)
KR (1) KR102893040B1 (enExample)
CN (1) CN113056274A (enExample)
AU (1) AU2019335409B2 (enExample)
CA (1) CA3111565A1 (enExample)
WO (1) WO2020051465A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113056274A (zh) 2018-09-07 2021-06-29 伊利诺伊大学评议会 具有降低的毒性的杂化两性霉素b衍生物
EP4009984A4 (en) * 2019-08-08 2023-09-06 The Board Of Trustees Of The University Of Illinois HYBRID AMPHOTERICIN B DERIVATIVES WITH REDUCED TOXICITY
AU2021325676A1 (en) * 2020-08-10 2023-03-30 The Board Of Trustees Of The University Of Illinois Hybrid amide derivatives of amphotericin B

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102548341B1 (ko) * 2013-10-07 2023-06-26 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 개선된 치료 지수를 갖는 암포테리신 b 유도체
JP6543272B2 (ja) 2014-05-16 2019-07-10 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイThe Board Of Trustees Of The University Of Illinois 低減された毒性を有するアンホテリシンb誘導体
MX378786B (es) * 2014-06-12 2025-03-11 Shionogi & Co Derivado de macrólido de polieno.
PT3283171T (pt) * 2015-04-15 2021-07-14 Sfunga Therapeutics Inc Derivados de anfotericina b
WO2017100171A1 (en) * 2015-12-08 2017-06-15 Kalyra Pharmaceuticals, Inc. Antifungal compounds and methods
CN113056274A (zh) 2018-09-07 2021-06-29 伊利诺伊大学评议会 具有降低的毒性的杂化两性霉素b衍生物

Similar Documents

Publication Publication Date Title
RU2336275C2 (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью, и фармацевтическая композиция
JP2020505396A5 (enExample)
RU2006131132A (ru) 1,3,5,-тризамещенные производные 4,5-дигидро-1н-пиразола, обладающие св1-антагонистической активностью
KR930702292A (ko) 종양 치료 활성을 증대시키기 위한 퀴나졸린 유도체
KR101605151B1 (ko) 화학요법에 의해 유도되는 통증의 예방 또는 치료를 위한 시그마 리간드
JP2003500404A5 (enExample)
RU2006134003A (ru) Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
KR20100080516A (ko) 아레나바이러스 감염을 치료하기 위한 항바이러스 약물
US20200392098A1 (en) SUBSTITUTED NAPHTHO[2,3-b]FURANS AS WATER-SOLUBLE PRODRUGS FOR PREVENTING AND/OR TREATING CANCER
JP2005507923A (ja) Ccr1受容体アンタゴニスト活性を有するピペラジン誘導体
JP5179190B2 (ja) 神経変性疾病の治療において1,4−ビス(3−アミノアルキル)ピペラジン誘導体を使用する方法
TNSN04188A1 (fr) NOUVEAUX DERIVES D'INDOLIZINE 1,2,3 SUBSTITUEE, INHIBITEURS DES FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
JP2023525359A5 (enExample)
JP5666442B2 (ja) パンクラチスタチンの窒素化誘導体
JP2024540303A5 (enExample)
RU2008136762A (ru) Циклические сульфоны как ингибиторы васе
JP2005511535A5 (enExample)
US20020198189A1 (en) New use
US3755584A (en) Tranquilizers
WO2017218959A1 (en) Porphyrin compounds and compositions useful for treating cancer
JP2004536079A5 (enExample)
RU2011108485A (ru) Новые (поли)аминоалкиламиноалкиламидные, алкилмочевинные или алкилсульфонамидные производные эпиподофиллотоксина, способ их получения и их применение в терапии в качестве противораковых средств
JP2006514051A5 (enExample)
JP2010535204A5 (enExample)
JP4699373B2 (ja) コルヒチン誘導体